Douglas K Graham

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia
    Douglas K Graham
    Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Cancer Res 12:2662-9. 2006
  2. ncbi BAC to the future? comparative genomic hybridization and genotyping pediatric leukemia cytogenetic abnormalities
    Douglas K Graham
    Department of Pediatrics, University of Colorado Denver and The Children s Hospital, Aurora, Colorado 80045, USA
    Pediatr Blood Cancer 51:153-4. 2008
  3. ncbi Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia
    Rachel M A Linger
    Department of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA
    Blood 114:2678-87. 2009
  4. ncbi Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress
    Adil Anwar
    Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA
    J Leukoc Biol 86:73-9. 2009
  5. ncbi Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity
    Amy K Keating
    Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA
    Mol Cancer Ther 9:1298-307. 2010
  6. ncbi Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus
    Justine Migdall-Wilson
    Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America
    PLoS ONE 7:e31635. 2012
  7. ncbi Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
    Rachel M A Linger
    University of Colorado Denver School of Medicine, Department of Pediatrics, Aurora, CO 80045, USA
    Expert Opin Ther Targets 14:1073-90. 2010
  8. ncbi Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children
    Abdulrahman Alsultan
    Center for Cancer and Blood Disorders, The Children s Hospital, University of Colorado Denver, Aurora, Colorado 80045, USA
    Pediatr Blood Cancer 52:626-30. 2009
  9. ncbi TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer
    Rachel M A Linger
    Department of Pediatrics, University of Colorado at Denver and Health Sciences Center, Aurora, CO, USA
    Adv Cancer Res 100:35-83. 2008
  10. ncbi A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation
    Susan Sather
    Department of Pediatrics, University of Colorado at Denver, and Health Sciences Center, Aurora, CO 80045, USA
    Blood 109:1026-33. 2007

Collaborators

Detail Information

Publications22

  1. ncbi Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia
    Douglas K Graham
    Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Cancer Res 12:2662-9. 2006
    ....
  2. ncbi BAC to the future? comparative genomic hybridization and genotyping pediatric leukemia cytogenetic abnormalities
    Douglas K Graham
    Department of Pediatrics, University of Colorado Denver and The Children s Hospital, Aurora, Colorado 80045, USA
    Pediatr Blood Cancer 51:153-4. 2008
  3. ncbi Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia
    Rachel M A Linger
    Department of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA
    Blood 114:2678-87. 2009
    ..This strategy may allow for dose reduction resulting in decreased toxicity and increased survival rates. Mer is aberrantly expressed in numerous other malignancies suggesting that this approach may have broad applications...
  4. ncbi Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress
    Adil Anwar
    Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA
    J Leukoc Biol 86:73-9. 2009
    ..These data represent the first report of Mer activation in response to oxidative stress and demonstrate the ability of Mer RTK to promote macrophage survival in disease states that involve an oxidative stress environment...
  5. ncbi Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity
    Amy K Keating
    Department of Pediatrics, University of Colorado Denver, Aurora, CO 80045, USA
    Mol Cancer Ther 9:1298-307. 2010
    ..Our results suggest Mer and Axl RTK inhibition as a novel method to improve apoptotic response and chemosensitivity in astrocytoma and provide support for these oncogenes as attractive biological targets for astrocytoma drug development...
  6. ncbi Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus
    Justine Migdall-Wilson
    Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States of America
    PLoS ONE 7:e31635. 2012
    ..Our results identify several novel features of Mer that expand the breadth of its functions and impact the development of therapeutic modalities designed to target Mer...
  7. ncbi Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
    Rachel M A Linger
    University of Colorado Denver School of Medicine, Department of Pediatrics, Aurora, CO 80045, USA
    Expert Opin Ther Targets 14:1073-90. 2010
    ..Studies demonstrating that Axl and Mer contribute to cell survival, migration, invasion, metastasis and chemosensitivity justify further investigation of Axl and Mer as novel therapeutic targets in cancer...
  8. ncbi Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children
    Abdulrahman Alsultan
    Center for Cancer and Blood Disorders, The Children s Hospital, University of Colorado Denver, Aurora, Colorado 80045, USA
    Pediatr Blood Cancer 52:626-30. 2009
    ....
  9. ncbi TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer
    Rachel M A Linger
    Department of Pediatrics, University of Colorado at Denver and Health Sciences Center, Aurora, CO, USA
    Adv Cancer Res 100:35-83. 2008
    ..Further research will be necessary to evaluate the full clinical implications of TAM family expression and activation in cancer...
  10. ncbi A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation
    Susan Sather
    Department of Pediatrics, University of Colorado at Denver, and Health Sciences Center, Aurora, CO 80045, USA
    Blood 109:1026-33. 2007
    ..Furthermore, soluble Mer decreased platelet aggregation in vitro and prevented fatal collagen/epinephrine-induced thromboembolism in mice, suggesting a potential therapeutic use for soluble Mer in the treatment of clotting disorders...
  11. ncbi Precursor natural killer cell leukemia
    Xiayuan Liang
    Department of Pathology, University of Colorado School of Medicine, Denver, USA
    Pediatr Blood Cancer 50:876-8. 2008
    ..Here we describe a pediatric patient with precursor NK cell leukemia and review the literature of the previously reported cases in children to further help characterize the diagnosis, treatment, and outcome...
  12. ncbi Thymoma in children: report of 2 cases and review of the literature
    Xiayuan Liang
    Department of Pathology, The Children s Hospital, Aurora, CO, USA
    Pediatr Dev Pathol 13:202-8. 2010
    ..The clinicopathologic features, differential diagnosis, and current therapeutic recommendations of this uncommon tumor in pediatric patients are also addressed...
  13. ncbi Natural killer cell neoplasms
    Xiayuan Liang
    Department of Pathology, Children s Hospital, Denver, Colorado, USA
    Cancer 112:1425-36. 2008
    ....
  14. ncbi Gray zone lymphomas in pediatric patients
    Xiayuan Liang
    Department of Pathology, The Children s Hospital, Aurora, CO, USA
    Pediatr Dev Pathol 14:57-63. 2011
    ..In this manuscript, we report 2 cases of pediatric patients with gray zone lymphoma and review clinicopathologic features, treatment options, and outcomes of this uncommon tumor...
  15. ncbi Disseminated nasopharyngeal natural killer cell lymphoblastic lymphoma in a child
    Douglas K Graham
    Department of Hematology, Oncology, and Bone Marrow Transplant, The Children's Hospital, University of Colorado Health Sciences Center, Denver, Colorado 80218, USA
    Med Pediatr Oncol 40:251-3. 2003
  16. ncbi Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development
    Alisa B Lee-Sherick
    Department of Paediatrics, Section of Haematology, Oncology, and Bone Marrow Transplantation, University of Colorado Denver School of Medicine, Aurora, CO, USA
    Br J Haematol 151:295-311. 2010
    ..This article explores many of the potential targeted therapies in varying stages of development, from those currently in clinical trials to those still being refined in the research laboratory...
  17. ncbi Moderate aplastic anemia in children: preliminary outcomes for treatment versus observation from a single-institutional experience
    Katharine Brock
    Department of Pediatrics, University of Colorado, Aurora, CO, USA
    J Pediatr Hematol Oncol 35:148-52. 2013
    ..On an exploratory basis, we sought to evaluate the influence of treatment with immunosuppressive therapy (IST) versus observation on long-term outcomes...
  18. ncbi Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission
    Sandra Christoph
    Department of Pediatrics, University of Colorado Denver, School of Medicine, 12800 E, 19th Ave, Aurora, CO, 80045, USA
    J Hematol Oncol 6:10. 2013
    ..abstract:..
  19. ncbi TAM receptors in leukemia: expression, signaling, and therapeutic implications
    LUIS BRANDAO
    Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA
    Crit Rev Oncog 16:47-63. 2011
    ..Finally, we discuss the current research focused on inhibitors against these receptors in an effort to develop new therapeutic strategies for leukemia...
  20. ncbi Molecular genetic analysis of a small bowel primitive neuroectodermal tumor
    Douglas K Graham
    Department of Hematology, Oncology, and Bone Marrow Transplant, The Children's Hospital, University of Colorado Health Sciences Center, Denver, CO 80218, USA
    Pediatr Dev Pathol 5:86-90. 2002
    ..This case report and a review of the literature underscore the considerable phenotypic overlap in EWS-related tumors in this site and the necessity for molecular genetic analysis to permit accurate classification...
  21. ncbi Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria
    Amy K Keating
    Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
    Mol Genet Metab 103:330-7. 2011
    ..Our findings indicate that anti-inflammatory strategies could serve as a useful adjuvant therapy for this disease...
  22. ncbi Successful treatment of severe aplastic anemia in children using standardized immunosuppressive therapy with antithymocyte globulin and cyclosporine A
    Neil A Goldenberg
    Division of Hematology, Oncology, and BMT, Department of Pediatrics, UCHSC The Children s Hospital, Denver, Colorado 80128, USA
    Pediatr Blood Cancer 43:718-22. 2004
    ..Given the heterogeneity of published data in US children, we sought to evaluate outcomes of a standardized immunosuppressive therapy (IST) regimen for severe aplastic anemia (SAA) at The Children's Hospital (Denver, CO)...